Q1 revenue $846.1M, down 16%; GAAP EPS $0.73, adjusted EPS $1.80

QuidelOrtho Corp

2023-Q1 EPS reported $0.73 revenue$846,100,000

Total revenue $846.1M, down 16% YoY; non-respiratory up 5% on supplemental combined basis.
GAAP EPS $0.73 vs $11.31; adjusted EPS $1.80 vs $8.03 on combined basis, down 78%.
Labs business drove non-respiratory growth with double-digit growth; respiratory revenue down 72%.
Adjusted EBITDA $245.3M (29% margin) vs $780.8M (52% margin) in prior year.
Integration on track; guidance to be provided on conference call; expects sustainable high-single-digit growth.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $846.1 million, EPS $0.73.

Period: first quarter ended April 2, 2023
Revenue: $846.1 million
EPS: $0.73
Result: reported results

Exact text from the filing

any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- QuidelOrtho Reports First Quarter 2023 Financial Results Highligh ts • First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-23-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.